title: Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine.
abstract: In an attempt to induce an immune response against tumour antigens, several groups are transfecting cytokine and other genes into autologous tumour cells which are given to the patient as a vaccine. This process is labour-intensive, time-consuming and expensive. Allogeneic cells would offer a more convenient vehicle for the delivery of cytokines and other molecules. However, current dogma suggests that MHC-matched cells are a prerequisite for an effective immune response. Using murine melanoma models we compared allogeneic and autologous vaccination and showed that the survival of C56BL/6 mice (H-2b) was prolonged with some degree of protection achieved against an autologous B15-F10 (H-2b) cell challenge when the mice were vaccinated with allogeneic K1735-M2 (H-2k) cells but not when immunized with autologous B16-F10 cells. Both vaccination with live and irradiated allogeneic cells induced an anti-tumour effect using only one immunization and no boost or adjuvant. Protection was not observed after vaccination with another melanoma (S91; H-2d) or with a carcinoma (A9HT; H-2k). Allogeneic vaccination promoted a cytotoxic cellular response against both the allogeneic and the syngeneic melanomas. This allogeneic vaccination model will be useful for studying the underlying mechanisms of protection, in both pre- and post-challenge settings, as well as for developing whole cell vaccination systems using genetically modified allogeneic tumour cells.
authors.affiliation: Division of Oncology, St George's Hospital Medical School, Tooting, London, UK.
authors.forename: B C
authors.initials: BC
authors.lastname: Knight
authors.forename: B E
authors.initials: BE
authors.lastname: Souberbielle
authors.forename: G P
authors.initials: GP
authors.lastname: Rizzardi
authors.forename: S E
authors.initials: SE
authors.lastname: Ball
authors.forename: A G
authors.initials: AG
authors.lastname: Dalgleish
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D005434:Flow Cytometry; D015395:Histocompatibility Antigens Class I / Q000032:analysis; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006801:Humans; D008546:Melanoma, Experimental / Q000276:immunology* / Q000517:prevention & control*; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D014407:Tumor Cells, Cultured / Q000528:radiation effects
chemical_list: D019496:Cancer Vaccines; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II